Danish Breast Cancer Cooperative Group

Christiansen, Peer; Ejlertsen, Bent; Jensen, Maj‐Britt; Mouridsen, Henning T.

doi:10.2147/clep.s99457

Cited by 94 publications

(73 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Previous quality assessments of the database have shown a near complete registration of breast cancer cases. 17,18 Using the unique civil registration number assigned to all Danish citizens, info on diagnosis from the DBCG was linked to the Danish Pathology Register, which contains detailed information on all human tissues examined by a pathological department in Denmark. 19 Information on death and emigration was obtained by linkage with the Civil Registration System.…”

Section: Registriesmentioning

confidence: 99%

Breast cancer mortality in synchronous bilateral breast cancer patients

et al. 2019

View full text Add to dashboard Cite

BACKGROUND: Evidence suggests that patients with synchronous bilateral breast cancer (SBBC), diagnosed within 4 months, have an inferior prognosis compared to unilateral breast cancer (UBC) patients. Using data from nationwide Danish clinical databases, this cohort study investigated whether the inferior prognosis could be explained by SBBC patients having a more aggressive disease, or whether the prognosis could be explained by the fact that they have two simultaneous cancers. METHODS: Patients were diagnosed from 1999-2015. The main outcome was excess mortality, subtracting background population mortality from observed mortality. Differences between SBBC and UBC patients were evaluated by rate ratios (RR) and estimated by Poisson regression. RESULTS: In total, 1214 SBBC and 59 177 UBC patients were included. SBBC patients had a significantly higher excess mortality than UBC patients after adjustment for age and period (RR = 1.73; 95% CI:1.44-2.08; p < 0.01) and after adjusting for characteristics of the worst tumour as traditionally done (RR = 1.31; 95% CI:1.08-1.57; p = 0.01). However, adjusting for characteristics of both tumours, using a more advanced competing risks model, no difference was observed (RR = 1.01; 95% CI:0.83-1.22; p = 0.93). CONCLUSIONS: Our study does not support that the inferior prognosis in SBBC patients is due to having more aggressive tumours per se, but rather the combined effect of having two simultaneous cancers.

show abstract

Section: Registriesmentioning

confidence: 99%

Breast cancer mortality in synchronous bilateral breast cancer patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Since 1977, Danish women with primary breast cancer have been registered in the Danish Breast Cancer Cooperative Group (DBCG) database including prospectively registered clinical data. Family history of breast and ovarian cancer was added to the Hereditary Breast and Ovarian Cancer (HBOC) register in 1999 [20]. From the DBCG database, Danish female BRCA1/2 carriers of BRCA mutation tested between 1997 and July 2011, with primary stage I-III breast cancer diagnosed between 1977 and February 2012, were included.…”

Section: Patientsmentioning

confidence: 99%

Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer

et al. 2019

View full text Add to dashboard Cite

Background: Patients with a BRCA1 or BRCA2 mutation (BRCA-mutated breast cancer) are frequently diagnosed with low differentiated and highly proliferating breast cancer characterized by high amounts of tumor-infiltrating lymphocytes (Tils). Stromal Tils (sTils) are highly prognostic in sporadic triple-negative and HER2 positive breast cancer however, their prognostic importance in BRCA-mutated breast cancers is unknown. Material and methods: Formalin-fixed paraffin-embedded primary tumor tissue from 411 patients with a germline BRCA1 or BRCA2 mutation and diagnosed with early breast cancer was included. The percentage of sTils was quantified on full HE sections according to guidelines proposed by the Immuno-Oncology Biomarker in Breast Cancer Working Group. Distribution of sTils and associates with patient and tumor characteristics were assessed according to categorical sTils groups defined as low (<10%), intermediate (10-59%) and high (!60%). Prognostic associations of sTils were evaluated as a continuous variable in univariate and multivariate models. Only follow-up time beyond date of BRCA mutation test was included. Results: A large proportion had high sTils (27% in the full cohort, 36% in BRCA1-mutated, and 44% in ER negative breast cancers). Higher sTils were associated with BRCA1, ER negative breast cancer, high histological grade and medullary histology. In combined analysis for BRCA1 and BRCA2-mutated breast cancers, increasing sTils in 10% intervals were significantly associated with OS (HR 0.92, 95% CI 0.84-1.00, p ¼ .05). For each 10% increment of sTils in BRCA1 breast cancers, a 10% reduction of mortality (adjusted HR 0.90 95% CI 0.81-0.99, p ¼ .03) and a 13% reduction in risk of DFS-event (HR 0.87 95% CI 0.76-1.00, p ¼ .05) was observed even after adjustment for ER status. No significant association with survival was of observed in the BRCA2 subgroup. Test for interaction of sTils and BRCA status was not statistically significant (p ¼ .3). Conclusions: Breast cancer patients with a germline BRCA mutation had higher sTils than previously reported in sporadic breast cancers, and sTils were associated with favorable survival among BRCA carriers. ARTICLE HISTORY

show abstract

“…The Danish Breast Cancer Cooperative Group (DBCG) [7] set up a phase-III trial comparing adjuvant letrozole for five years with neoadjuvant letrozole for four months combined with adjuvant letrozole to a total of five years following stable disease or response and combined with adjuvant chemotherapy following progressive disease. The original phase-III design was abandoned due to slow accrual and the trial was converted to a single arm phase-II trial.…”

Section: Introductionmentioning

confidence: 99%